Peter de Nully Brown

Peter de Nully Brown serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen, specializing in Internal Medicine: Haematology. Based at Blegdamsvej 3, 2200 Copenhagen N, Denmark, he maintains active clinical and research roles with contact details including phone +4535451128 and email peter.brown@regionh.dk.

His research centers on lymphoma epidemiology, particularly Diffuse Large B-Cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL), leveraging Denmark's nationwide registries for real-world evidence generation. Key focus areas include:

• Validation of prognostic indices and clinical nomograms
• Impact of age and biomarkers on treatment efficacy
• Secondary CNS involvement in lymphoma
• Long-term immune complications in survivors
• Symptom burden (fatigue/pain/insomnia) in cancer survivorship
• Real-world outcomes of targeted therapies like ibrutinib

Analysis of his 2025 publications reveals a cohesive research program emphasizing population-based methodologies to address critical gaps in lymphoma management. His work consistently bridges epidemiological rigor with clinical applicability, particularly in risk stratification for elderly patients and validation of trial eligibility criteria using real-world data. A distinctive pattern involves multi-institutional Danish collaborations examining nationwide cohorts to generate generalizable evidence for hemato-oncology practice.

No scientific awards were specified in the provided information.

While specific student advising details are absent, his extensive co-authorship network across 105 publications indicates mentorship within large research teams. Grant funding is implied through nationwide registry studies but not explicitly detailed. His collaborative footprint spans Rigshospitalet (evidenced by regionh.dk email domain) and national cancer consortia.

Dr. Brown operates within Denmark's integrated healthcare-research infrastructure, coordinating with the Danish Cancer Society and National Patient Registry. He participates in the Danish Lymphoma Group and contributes to population-based studies requiring cross-institutional data harmonization, reflecting leadership in national hemato-oncology research networks.